A detailed history of China Universal Asset Management Co., Ltd. transactions in Edgewise Therapeutics, Inc. stock. As of the latest transaction made, China Universal Asset Management Co., Ltd. holds 18,035 shares of EWTX stock, worth $555,117. This represents 0.05% of its overall portfolio holdings.

Number of Shares
18,035
Previous 10,973 64.36%
Holding current value
$555,117
Previous $197,000 144.16%
% of portfolio
0.05%
Previous 0.03%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 25, 2024

BUY
$15.88 - $29.5 $112,144 - $208,329
7,062 Added 64.36%
18,035 $481,000
Q2 2024

Jul 19, 2024

SELL
$15.08 - $21.23 $104,172 - $146,656
-6,908 Reduced 38.63%
10,973 $197,000
Q1 2024

Apr 29, 2024

BUY
$9.25 - $19.97 $97,522 - $210,543
10,543 Added 143.68%
17,881 $326,000
Q4 2023

May 21, 2024

SELL
$5.51 - $12.1 $58,091 - $127,570
-10,543 Reduced 58.96%
7,338 $80,000
Q4 2023

Jan 23, 2024

BUY
$5.51 - $12.1 $31,429 - $69,018
5,704 Added 349.08%
7,338 $80,000
Q3 2023

May 21, 2024

BUY
$5.73 - $7.69 $4,612 - $6,190
805 Added 97.1%
1,634 $9,000
Q3 2023

Oct 30, 2023

BUY
$5.73 - $7.69 $4,612 - $6,190
805 Added 97.1%
1,634 $9,000
Q2 2023

May 21, 2024

SELL
$5.71 - $10.29 $159 - $288
-28 Reduced 3.27%
829 $6,000
Q2 2023

Jul 27, 2023

SELL
$5.71 - $10.29 $159 - $288
-28 Reduced 3.27%
829 $6,000
Q1 2023

May 21, 2024

BUY
$6.66 - $11.33 $1,431 - $2,435
215 Added 33.49%
857 $5,000
Q1 2023

Apr 27, 2023

BUY
$6.66 - $11.33 $1,431 - $2,435
215 Added 33.49%
857 $6,000
Q4 2022

May 21, 2024

SELL
$7.58 - $11.08 $130,671 - $191,008
-17,239 Reduced 96.41%
642 $5,000
Q4 2022

Jan 31, 2023

BUY
$7.58 - $11.08 $1,326 - $1,939
175 Added 37.47%
642 $6,000
Q3 2022

Oct 21, 2022

BUY
$8.08 - $13.58 $3,773 - $6,341
467 New
467 $5,000

Others Institutions Holding EWTX

About Edgewise Therapeutics, Inc.


  • Ticker EWTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 63,171,700
  • Market Cap $1.94B
  • Description
  • Edgewise Therapeutics, Inc., a biopharmaceutical company, develops small molecule therapies for musculoskeletal diseases. The Company's lead product candidate, EDG-5506, is an orally administered small molecule designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy which has c...
More about EWTX
Track This Portfolio

Track China Universal Asset Management Co., Ltd. Portfolio

Follow China Universal Asset Management Co., Ltd. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of China Universal Asset Management Co., Ltd., based on Form 13F filings with the SEC.

News

Stay updated on China Universal Asset Management Co., Ltd. with notifications on news.